LEQEMBI Subcutaneous Formulation Approved in China for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. announced that China's National Medical Products Administration (NMPA) has approved the subcutaneous formulation of LEQEMBI (lecanemab) as an initiation treatment for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. This approval introduces a new once-weekly, self-administered option for patients at home, offering greater flexibility and potentially reducing the burden of clinic visits compared to the existing intravenous administration.